Faculty Profile

Larry D. Lynd

PhD, BSP, FCAHS
Associate Dean, Research; Professor and Director, Collaboration for Outcomes Research and Evaluation (CORE)
Office of the Associate Dean, Research

Other Affiliations

Scientist, Centre for Health Evaluation and Outcome Sciences (CHEOS), Providence Health Care Research Institute

Contact Information

Primary Phone Number (604) 827-3397
Email Address larry.lynd@ubc.ca
Office 4112, 5501, Pharmaceutical Sciences Building

Selected Publications

Borle K, Kopac N, Dragojlovic N, Rodriguez-Llorian E, Friedman JM, GenCOUNSEL Study, Elliot AM, Lynd LD. Where is genetic medicine headed? Exploring the perspectives of Canadian genetic professionals on future trends using the Delphi method. Eur J Hum Genetics 2021: In Press.

Douglas CMW, Panagiotoglou D, Dragojlovic N, Lynd LD. Methodology for constructing scenarios for health policy research: The case of coverage decision-making for drugs for rare diseases in Canada. Technol Forecast Soc Change 2021; 171 (120960): https://doi.org/10.1016/j.techfore.2021.120960

Oh J, Arbour N, Giuliani F, Guenette M, Kolind S, Lynd LD, Ruth AM, Metz LM, Patten SB, Prat A, Schabas, A, Smyth P, Tam, R, Traboulsee A, Wee Yong V. The Canadian prospective cohort study to understand progression in multiple sclerosis (CanProCo): rationale, aims, and study design. BMC Neurol 2021; 21 (418): https://doi.org/10.1186/s12883-021-02447-7

Ho JK, Borle K, Dragojlovic N, Dhillon M, Kitchin V, Kopac N, Ross C, Lynd LD. Economic evidence of potential curative gene therapy products: a systematic literature review. PharmacoEconomics 2021: https://doi.org/10.1007/s40273-021-01051-4

Dragojlovic N, Kopac N, Borle K, Tandun R, Salmasi S, Ellis U, Birch P, Adan S, Friedman J, Elliot AM, Lynd LD. Utilization and uptake of clinical genetics services in high income countries: a scoping review. Health Policy 2020: In Press. https://doi.org/10.1016/j.healthpol.2021.04.010

Hategeka C, Ruton H, Karamouzian M, Lynd LD, Law MR. Use of interrupted time series methods in the evaluation of health system quality improvement interventions: a methodologic systematic review. BMJ Global Health 2020;5:e003567. http://dx.doi.org/10.1136/bmjgh-2020-003567

Dragojlovic N, Borle K, Kopac N, Ellis U, Birch P, Adam S, Friedman JM, Nisselle A, GenCOUNSEL Study, Elliott AM, Lynd LD. The composition and capacity of the clinical genetics workforce in high-income countries: a scoping review. Genet Med 2020; 22: 1437-49. https://doi.org/10.1038/s41436-020-0825-2

Awards

Dr. John McNeil Excellence in Health Research Mentorship Award 2022

Fellow. Lynd LD. Canadian Academy of Health Sciences. 2018.

PharmD Teaching Award. Lynd LD. UBC Faculty of Pharmaceutical Sciences. 2014-2015.

Grants

“An early Health Technology Assessment (eHTA) platform to inform nanomedicine development decisions and improve commercialization success.” Lynd LD (PI). $240,000. NanoMedicines Innovation Network (NMIN) Strategic Initiatives. 2021-2024.

“Predictive modeling in multiple sclerosis: using real world data to inform practice, policy, and research.” Lynd LD (Co-PI). $615,000. Canadian Institutes for Health Research. 2021 – 2025.

“Implementation of diagnostic genome sequencing for rare diseases in British Columbia.” Lynd LD (Co-PI). $2,900,000. Genome Canada. 2020-2023.

“The Canadian Prospective Cohort Study of Progression in Patients with Multiple Sclerosis (CanProCo).” Lynd LD (Co-PI). $1,718,000. MS Society of Canada. 2018-2023

“GenCOUNSEL: Optimization of Genetic Counseling for Clinical Implementation of Genome-Wide Sequencing.” Lynd LD (Co-PI). $1,050,000. Genome British Columbia (administrative lead), Génome Québec. 2018-2022.

Presentations

“Diagnosis and treatment of rare diseases: the need to innovate to enable access.” Lynd LD. The joint meeting of 8th annual Canadian Human and Statistical Genetics Meeting and CIHR Institute of Genetics Canadian GE3LS* and Health Services Policy Meeting. Montreal, QC. June 16 – 19, 2019.

“When zebras run with horses: the impact of treatment for rare disease on mainstream medicine.” Lynd LD. Canadian Society of Nephrology Annual General Meeting and Renal Pharmacists Network Joint Session. Montreal, QC. May 4, 2019.

“Orphan Drugs for Rare Diseases: the need to innovate to enable access.” Lynd LD. Telus Health Annual Conference. Vancouver, BC. April 10, 2019.

“Orphan Drugs for Rare Diseases: the need to innovate to enable access.” Lynd LD. Telus Health Annual Conference. Toronto, ON. April 2, 2019.

“Orphan Drugs for Rare Diseases: the need to innovate to enable access.” Lynd LD. Canadian Institutes for Health Research Socioeconomic Burden of Rare Diseases Workshop. Ottawa, ON. March 21, 2019.

“The need for innovation to enable access to diagnosis and treatment of rare diseases.” Lynd LD. Life Sciences BC Access to Innovation 2019. Vancouver, BC. January 30, 2019.

“Expensive drugs for rare disease – challenges in evaluation and access.” Lynd LD. Provincial Renal Grand Rounds. Vancouver General Hospital. Vancouver, BC. April 6, 2018.

“Using big data to inform practice, policy, and research – a Canadian experience.” Lynd LD. 2017 Drug Utilization Research Conference. Rio de Janeiro, Brazil. September 2017.

“Prescription to over-the-counter: potential unintended consequences.” Lynd LD. Healthy Canada Conference 2017: Access to Affordable Medicines. Toronto, ON. April 26, 2017.

“Evaluating provincial challenges and opportunities around orphan drugs.” Lynd LD. 15th Annual Market Access Summit. Toronto, ON. November 16, 2016.

“Developing a Canadian framework for evaluation and decision-making for rare diseases.” Lynd LD. Delivering Innovation: a Moon Shot for Rare Disorders and Beyond. Toronto, ON. November 6-7, 2017.

“Using big data to inform practice, policy, and research.” Lynd LD. International Summit Forum on Prevention and Precision Medicine of Infectious Diseases. Shenzhen, China. October 13, 2016.

“The Canadian orphan drug framework in context – implications for patients, practice, and society.” Lynd LD. Garrod Symposium. Halifax, NS. May 21, 2016.

“Exploring Contemporary Pressures on Pharmaceutical Reimbursement in an Era of Orphan Drugs and Personalized Medicine.” Lynd LD. 2016 CADTH Symposium. Ottawa, ON. April 12, 2016.

“Using big data to inform practice, policy, and research.” Lynd LD. The Data Effect meeting. Vancouver, BC. March 11, 2016.

"Can we move from sick-care to health-care?" Lynd LD. LSI Public Talks, Personalized Medicine: Your Life, Your Genes, Your Health and Happiness. Vancouver, BC. February 4, 2015.

"Evaluating the implications of orphan drugs and rare diseases in Canada – a reimbursement/health care sustainability perspective." Lynd LD. UBC Faculty of Pharmaceutical Sciences Seminar Series. Vancouver, BC. October 8, 2014.

"Providing professional pharmacy services in British Columbia – implementation, evaluation, and reimbursement." Lynd LD. The 15th Annual Congress of the Soceity Francaise de Pharmacie Clinique (SFPC). Grenoble, FR. February 7, 2014.

"Using state choice methods in health services research and evaluation." Lynd LD. Universitè Joseph Fournier. February 5, 2014. Grenoble, FR. February 5, 2014. "Personalized medicine, orphan disease drugs, and the future of health economics." Lynd LD. Panelist and Speaker. The 9th World Congress on Health Economics. Sydney, AU. July 10, 2013.

About

Dr. Lynd is a pharmacist, epidemiologist, and health outcomes researcher. He completed his PhD in the Department of Health Care and Epidemiology at UBC and his post-doctoral fellowship in health economics at McMaster University. Currently, Dr. Lynd is Associate Dean, Research; Professor and Director of the Collaboration for Outcomes Research and Evaluation (CORE) at the UBC Faculty of Pharmaceutical Sciences; at the Centre for Health Evaluation and Outcomes Sciences at the Providence Health Research Institute; Scholar at the Peter Wall Institute of Advanced Studies; and Associate of the UBC School of Population and Public Health.

Dr. Lynd’s research focuses on the integration of epidemiologic and health economic analyses on health outcomes, including the use of large administrative health datasets, to inform practice, policy, and research. His primary areas of research include the testing and treatment of rare diseases, multiple sclerosis, and respiratory disease. He is the lead of the epidemiology/health economics themes for the: CANadian PROactive Cohort study for People Living with MS, a 5-year pan-Canadian prospective cohort study in multiple sclerosis; the GenCOUNSEL study, evaluating the implementation of whole genome sequencing for the provision of clinical genetic services (www.bcchr.ca/GenCOUNSEL); and, the Early Health Technology Assessment platform for the Nanomedicines Innovation Network (www.nanomedicines.ca).

Dr. Lynd has made significant contributions serving on a number of committees, including chair of the Health Canada Special Advisory Committee on Non-Prescription Drugs, Special Advisory Committee to the Respiratory and Allergy Therapies Division of Health Canada, BC Ministry of Health Services Expensive Drugs for Rare Diseases Committee, and the BC PharmaNet Data Stewardship Committee.